Sp1 regulates cathepsin B transcription and invasiveness in murine B16 melanoma cells

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 3887-3891

  Szpaderska, Anna M ^a   Silberman, Simone ^a   Ahmed, Yasmin ^a   Frankfater, Allen ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CA 074; Cancer; Cathepsin B; Invasion; Matrigel; Sp1 transcription factor

Indexed keywords

CA 074; CATHEPSIN B; CATHEPSIN B INHIBITOR; MATRIGEL; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; COLLAGEN; LAMININ; PROTEOGLYCAN;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER INVASION; CELL MEMBRANE; CELL MOTILITY; CONTROLLED STUDY; DEGRADATION; EXTRACELLULAR MATRIX; MELANOMA CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; ANIMAL; BASEMENT MEMBRANE; BIOSYNTHESIS; CELL MOTION; DRUG COMBINATION; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BASEMENT MEMBRANE; CATHEPSIN B; CELL MOVEMENT; COLLAGEN; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; LAMININ; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; PROTEOGLYCANS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 14944345444     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Yan S, Sameni M and Sloane BF: Cathepsin B and human tumor progression. Biol Chem 379: 113-123, 1998.
2. Qian F, Bajkowski AS, Steiner DF, Chan SJ and Frankfater A: Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res 49: 4870-4875, 1989.
3. Khan A, Krishna M, Baker SP, Malhothra R and Banner BF: Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch Pathol Lab Med 122: 172-177, 1998.
4. Chambers AF, Colella R, Denhardt DT and Wilson SM: Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinog 5: 238-245, 1992.
5. Strojan P, Budihna M, Smid L, Svetic B, Vrhovec I, Kos J and Skrk J: Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 1052-1062, 2000.
6. Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J and Mach L: Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C. Int J Cancer 83: 526-531, 1999.
7. Krueger S, Haeckel C, Buehling F and Roessner A: Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 59: 6010-6014, 1999.
8. Szpaderska AM and Frankfater A: An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 61: 3493-3500, 2001.
9. Sameni M, Moin K and Sloane BF: Imaging proteolysis by living human breast cancer cells. Neoplasia 2: 496-504, 2000.
10. Qian F, Chan SJ, Achkar C, Steiner DF and Frankfater A: Transcriptional regulation of cathepsin B expression in B16 melanomas of varying metastatic potential. Biochem Biophys Res Commun 202: 429-436, 1994.
11. Courey AJ and Tjian R: Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55: 887-898, 1988.
12. Dignam JD, Lebovitz RM and Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983.
13. Janulis M, Silberman S, Ambegaokar A, Gutkind JS and Schultz RM: Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. J Biol Chem 274: 801-813, 1999.
14. Chan SJ, San Segundo B, McCormick MB and Steiner DF: Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. Proc Natl Acad Sci USA 83: 7721-7725, 1986.
15. Rhaissi H, Bechet D and Ferrara M: Multiple leader sequences for mouse cathepsin B mRNA? Biochimie 75: 899-904, 1993.
16. Brenner CA, Tam AW, Nelson PA, Engleman EG, Suzuki N, Fry KE and Larrick JW: Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 7: 1096-1103, 1989.
17. Yan S, Berquin IM, Troen BR and Sloane BF: Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol 19: 79-91, 2000.
18. Kumar AP and Butler AP: Enhanced Sp1 DNA-binding activity in murine keratinocyte cell lines and epidermal tumors. Cancer Lett 137: 159-165, 1999.
19. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H and Inoue M: Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669-677, 2000.
20. Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J and Mudryj M: Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 20: 5737-5747, 2001.
21. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K and Sueishi K: Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 60: 6531-6536, 2000.
22. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ and Boyd DD: Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 274: 18428-18437, 1999.
23. Ibanez-Tallon I, Ferrai C, Longobardi E, Facetti I, Blasi F and Crippa MP: Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA gene and invasive potential of PC3 cells. Blood 100: 3325-3332, 2002.
24. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP and Kojima S: Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 93: 4264-4276, 1999.
25. Merchiers P, Bulens F, De Vriese A, Collen D and Belayew A: Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue-type plasminogen activator gene. FEBS Lett 456: 149-154, 1999.
26. Cha HJ, Okada A, Kim KW, Sato H and Seiki M: Identification of cis-acting promoter elements that support expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) in v-src transformed Madin-Darby canine kidney cells. Clin Exp Metastasis 18: 675-681, 2000.
27. Qin H, Sun Y and Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274: 29130-29137, 1999.
28. Mohan R, Rinehart WB, Bargagna-Mohan P and Fini ME: Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling. J Biol Chem 273: 25903-25914, 1998.
29. Wang F, Wang W and Safe S: Regulation of constitutive gene expression through interactions of Sp1 protein with the nuclear aryl hydrocarbon receptor complex. Biochemistry 38: 11490-11500, 1999.
30. Jean D, Guillaume N and Frade R: Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J 361: 173-184, 2002.